Tianda Pharmaceuticals Ltd. (0455) AI Stock Analysis

• Market Cap: HK$268.76M
• Dividend Yield: N/A
• Average Volume (3M): 84.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: -19.28%
• EPS Growth: -42.27%
• Country: HK
• Employees: 701
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.02
• Shares Outstanding: 2,150,041,700
• 10 Day Avg. Volume: 115,400
• 30 Day Avg. Volume: 84,945
• PEG Ratio: -0.04
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 1.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: HK$0.12 ▼(-10.00% Downside)

The score is primarily held down by weak financial performance, including declining revenue, ongoing losses, and negative operating cash flow. Technical indicators are mixed with only modest near-term improvement against a longer-term downtrend, while valuation is constrained by negative earnings (negative P/E) and no provided dividend yield.

Positive Factors

Diversified revenue streams

Multiple product channels (prescription, OTC, TCM) plus licensing and distribution reduce concentration risk and support revenue resilience. This multi-pronged model enables cross-selling, geographic expansion via partners, and recurring licensing upside that can sustain earnings over months.

Manageable leverage

A low-to-moderate debt load preserves financial flexibility to fund R&D or working capital without excessive interest strain. Manageable leverage lowers refinancing risk and gives the company room to pursue strategic investments or absorb temporary revenue shortfalls over the medium term.

Stable gross profit margin

Stable gross margins imply core product economics and pricing power are intact, which supports long-term profitability recovery if top-line stabilizes. Maintaining unit economics helps absorb SG&A and R&D while enabling margin recovery as scale returns over several quarters.

Negative Factors

Declining revenue trend

Sustained top-line contraction undermines scale and the company’s ability to cover fixed costs, invest in new products, and support commercial expansion. Continued revenue declines over multiple quarters elevate the risk that cost cuts will be needed, harming long-term growth potential.

Negative operating cash flow

Persistent negative operating cash flow signals the business cannot internally fund operations or capex, forcing reliance on external financing. Over months this constrains R&D, marketing, and working capital, increasing liquidity and execution risk during turnaround attempts.

Persistent losses and negative ROE

Ongoing unprofitability and negative ROE erode shareholder value and limit reinvestment capacity. Persistent losses reduce retained earnings, pressure equity cushions, and make raising capital costlier, hindering sustainable growth and long-term competitiveness unless profitability is restored.

Tianda Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. Its product range includes Chinese medicines, chemical drugs, biological and health products, and medical appliances covering the area of cardio-cerebrovascular, pediatric, anti-flu and respiratory, anti-infection, detoxification, urological agents, and others. The company offers its health products under the Herb Valley and Tuokang brands. It also engages in the sale and wholesale of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicines; provision of Chinese medical services; and trading of agricultural by-products. The company was formerly known as Tianda Holdings Limited and changed its name to Tianda Pharmaceuticals Limited in September 2012. The company was incorporated in 1992 and is headquartered in Central, Hong Kong. Tianda Pharmaceuticals Limited is a subsidiary of Tianda Group Limited.

How the Company Makes Money

Tianda Pharmaceuticals generates revenue through multiple streams, including the sale of prescription medications, OTC products, and traditional Chinese medicine. The company's revenue model is based on direct sales to healthcare providers, pharmacies, and hospitals, as well as distribution agreements with third-party partners. Key revenue streams include the licensing of its proprietary products and formulations, which allows the company to expand its market reach. Additionally, Tianda may benefit from collaborations with research institutions or other pharmaceutical companies that enhance its product development capabilities and market presence. Factors contributing to its earnings also include market demand for its diversified product portfolio and strategic marketing initiatives aimed at increasing brand awareness.

Tianda Pharmaceuticals Ltd. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	384.68M	329.94M	532.09M	546.69M	509.96M	474.33M
Gross Profit	176.28M	152.02M	255.53M	251.52M	241.22M	258.99M
EBITDA	-9.97M	-49.49M	15.66M	-19.89M	-5.14M	-6.25M
Net Income	-47.26M	-61.37M	-24.16M	-54.64M	-21.67M	-25.92M
Balance Sheet
Total Assets	804.77M	765.02M	917.29M	1.09B	1.16B	1.13B
Cash, Cash Equivalents and Short-Term Investments	103.77M	85.69M	162.44M	343.44M	334.00M	234.98M
Total Debt	98.81M	127.44M	113.60M	141.05M	160.43M	145.53M
Total Liabilities	260.34M	259.36M	325.35M	434.23M	375.08M	342.97M
Stockholders Equity	544.55M	505.84M	592.07M	627.83M	756.75M	756.71M
Cash Flow
Free Cash Flow	-43.08M	-52.30M	-116.04M	54.73M	-61.98M	-184.08M
Operating Cash Flow	-26.10M	-9.70M	-49.76M	79.11M	-8.23M	-37.63M
Investing Cash Flow	-42.53M	-31.77M	-69.10M	-12.20M	86.35M	-137.73M
Financing Cash Flow	-59.61M	-30.65M	-57.39M	-28.98M	-1.29M	90.75M

Tianda Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0455, the sentiment is Negative. The current price of 0.13 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.12, and below the 200-day MA of 0.15, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 49.84 is Neutral, neither overbought nor oversold. The STOCH value of 46.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0455.

Tianda Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8329	54 Neutral	HK$258.41M	39.49	0.72%	3.51%	-5.98%	-81.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1652	49 Neutral	HK$595.53M	-3.16	-40.38%	―	-43.46%	-96.48%
1011	48 Neutral	HK$573.11M	-3.37	―	―	―	―
8622	48 Neutral	HK$211.34M	-40.20	-8.71%	―	2.54%	33.33%
0897	46 Neutral	HK$410.66M	-29.67	-1.16%	7.50%	59.60%	-351.02%
0455	44 Neutral	HK$268.76M	-3.99	-13.08%	―	-19.28%	-42.27%